As an Instructor of the Division of Clinical Immunology and Rheumatology, Dr. Aaron Silva-Sanchez focuses his research on understanding the origin and function of neonatal regulatory dendritic cells (mregDCs) and their role in controlling CD8 T cell responses.
Dr. Silva-Sanchez graduated with a Ph.D. in Immunology from the National School of Biomedical Sciences in Mexico City. He joined UAB as a postdoctoral fellow in 2011 to work with Dr. Harry Schroeder on the study of mice with altered B cell receptor repertoire and the production of anti-DNA antibodies.
In 2013, Dr. Silva-Sanchez joined the laboratory of Troy Randall where he researched the development and immunological impact of the inducible Bronchus-Associated Lymphoid Tissue (iBALT), a type of tertiary lymphoid structures in the lung. During this period, Dr. Silva-Sanchez also studied the pulmonary immune system of neonate mice in order to understand the immunological mechanisms responsible for increased susceptibility to viral infections during early life.
During the Covid-19 pandemic, Dr. Silva-Sanchez formed part of the task force in charge of developing the preclinical trials for an intranasal vaccine against SARS-CoV-2 in collaboration with Dr. Frances Lund, Southeastern Biosafety Laboratory Alabama Birmingham (SEBLAB), and Altimmune, Inc.